In accordance with our findings, Dome et al. demonstrated higher numbers of CD34+ VEGFR2+ double-positive cells in the peripheral blood of non-small cell lung cancer patients in comparison with healthy controls and identified CD34+ VEGFR2+ double-positive cells as a progression marker5. This evidence concerns the gene CD34 and non-small cell lung carcinoma.